Introduction Cerebrospinal fluid (CSF) biomarkers can identify individuals with Alzheimer's
disease (AD) pathology (eg, amyloid plaques, neurofibrillary tangles), but defined analyte …

INTRODUCTION We assessed the concordance of cerebrospinal fluid (CSF) amyloid beta
(Aβ) and tau measured on the fully automated Lumipulse platform with pre‐symptomatic …

Introduction Levels of amyloid β peptide 42 (Aβ42), total tau, and phosphorylated tau-181
are well-established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, but …

Objective To determine the cutoffs that optimized the agreement between 18F‐Florbetapir
positron emission tomography (PET) and Aβ1‐42, Aβ1‐40, tTau, pTau and their ratios …

Introduction We aimed to provide cut points for the automated Elecsys Alzheimer's disease
(AD) cerebrospinal fluid (CSF) biomarkers. Methods Cut points for Elecsys amyloid beta 42 …

Importance Cerebrospinal fluid (CSF) and positron emission tomographic (PET) amyloid
biomarkers have been proposed for the detection of Alzheimer disease (AD) pathology in …

Introduction We evaluated for two novel automated biomarker assays how cerebrospinal
fluid (CSF) amyloid beta (Aβ) 1–42‐ratios improved the concordance with amyloid positron …

Background Cerebrospinal fluid (CSF) biomarkers are increasingly used to diagnose
Alzheimer's disease (AD). However, important methodological and technical remain …

Introduction Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p‐
tau] and total tau [t‐tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical …

Background The recent promise of disease-modifying therapies for Alzheimer's disease
(AD) has reinforced the need for accurate biomarkers for early disease detection, diagnosis …